Neurogene (NGNE) Change in Account Payables (2023 - 2026)
Neurogene (NGNE) reported Change in Account Payables of $2.4 million for Q1 2026, up 42.98% on a YoY basis from $1.7 million in Q1 2025, and up 492.18% quarter-over-quarter from $409000.0 in Q4 2025.
Neurogene (NGNE) Change in Account Payables (2023 - 2026) Analysis & Trends
Neurogene has reported Change in Account Payables for 4 years, with the latest figure at $2.4 million in Q1 2026.
- For the quarter ending Q1 2026, Change in Account Payables rose 42.98% year-over-year to $2.4 million; the trailing twelve-month figure through Mar 2026 stood at $1.4 million (down 8.57% YoY), and the FY2025 full-year result was $627000.0, up 914.29% from the prior year.
- Change in Account Payables for Q1 2026 stood at $2.4 million, up from $409000.0 in the prior quarter.
- The five-year high for Change in Account Payables was $2.4 million in Q1 2026, with the low at -$975000.0 in Q2 2025.
- Historically, Change in Account Payables has averaged $279923.1 across 4 years, with a median of $135000.0 in 2024.
- The largest YoY upside for Change in Account Payables was 1154.81% in 2025 against a maximum downside of 1627.59% in 2025.
- Neurogene's Change in Account Payables stood at -$842000.0 in 2023, then soared by 50.59% to -$416000.0 in 2024, then soared by 198.32% to $409000.0 in 2025, then jumped by 492.18% to $2.4 million in 2026.
- The last three Change in Account Payables figures came in at $2.4 million (Q1 2026), $409000.0 (Q4 2025), and -$501000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -3.26 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 35.60 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -9.42 Mn |
| 10 | Neurogene | 216.17 Mn | 216.17 Mn | - | 2.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.42 Mn |
| Mar 31, 2026 | 2.42 Mn |
| Dec 31, 2025 | 409,000.00 |
| Dec 31, 2025 | 409,000.00 |
| Sep 30, 2025 | -501,000.00 |
| Sep 30, 2025 | -501,000.00 |
| Jun 30, 2025 | -975,000.00 |
| Jun 30, 2025 | -975,000.00 |
| Mar 31, 2025 | 1.69 Mn |
| Mar 31, 2025 | 1.69 Mn |
| Dec 31, 2024 | -416,000.00 |
| Dec 31, 2024 | -416,000.00 |
| Sep 30, 2024 | -29,000.00 |
| Sep 30, 2024 | -29,000.00 |
| Jun 30, 2024 | 233,000.00 |
| Jun 30, 2024 | 233,000.00 |
| Mar 31, 2024 | 135,000.00 |
| Mar 31, 2024 | 135,000.00 |
| Dec 31, 2023 | -842,000.00 |
| Dec 31, 2023 | -842,000.00 |